Arai, Hiroyuki http://orcid.org/0000-0002-1886-7070
Elliott, Andrew
Millstein, Joshua
Xiu, Joanne
Ou, Fang-Shu
Innocenti, Federico
Wang, Jingyuan
Battaglin, Francesca
Jayachandran, Priya
Kawanishi, Natsuko
Soni, Shivani
Zhang, Wu
Sohal, Davendra
Goldberg, Richard M.
Hall, Michael J.
Scott, Aaron J.
Khushman, Mohd
Hwang, Jimmy J.
Lou, Emil
Weinberg, Benjamin A.
Lockhart, Albert Craig
Shields, Anthony Frank
Abraham, Jim P.
Magee, Daniel
Stafford, Phillip
Zhang, Jian
Venook, Alan P.
Korn, W. Michael
Lenz, Heinz-Josef http://orcid.org/0000-0003-2178-9568
Funding for this research was provided by:
Dhont Family Foundation
Article History
Received: 13 August 2021
Revised: 1 October 2021
Accepted: 8 October 2021
First Online: 2 November 2021
Competing interests
: DS reports consulting role for Ability Pharmaceuticals, honoraria from Foundation Medicine, Speakers bureau from Incyte, and research funding at institution from Amgen, Apexigen, Bristol-Myers Squibb, Celgene, FibroGen, Genentech, Medimmune, Merck, OncoMed, and Rafael. RMG reports consulting/advisory role for Merck, Taiho Pharmaceutical, Merck KGaA and Novartis, research funding from Bristol-Myers Squibb, and travel paid from Merck KGaA and Merck. WMK reports consulting role for Merck. HJL reports a role of advisory board for Merck KG, Merck, Bayer, Roche/Genentech, G1 Therapeutics, Oncocyte, Fulgent, Jazz Therapeutics, and Bicara. AE, JX, JPA, DM, PS, JZ, and WMK are Caris employee. All remaining authors declare no competing interests.